Clinical Advances in Nasopharyngeal Carcinoma - Episode 9

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

, ,

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma
EP. 3: Overview of the JUPITER and POLARIS-2 Trials
EP. 4: Value of PD-L1 Biomarker in NPC
EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
Now Viewing
EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
EP. 10: Clinical Scenario: Locally Recurrent NPC

Video content above is prompted by the following:

What are the potential benefits of integrating PD-1 inhibitors into standard treatment protocols for NPC?

  • What does the future look like for PD-1 Inhibitors in NPC?